Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Navidea Biopharmaceuticals, Inc (NAVB)

1.66 0.00(0.00%) Apr 17, 4:06PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Navidea Biopharmaceuticals, Inc
5600 Blazer Parkway
Suite 200
Dublin, OH 43017
United States - Map
Phone: 614-793-7500
Fax: 614-793-7522

Index Membership:N/A
Industry:Medical Appliances & Equipment
Full Time Employees:57

Business Summary 

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company’s radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in lymphatic mapping procedures, which are performed to evaluate breast cancer and melanoma; Manocept platform to target the CD206 mannose receptor expressed on macrophages; and NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer’s disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders with potential use as a diagnostic aid in dementia; and NAV1800, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Navidea Biopharmaceuticals, Inc

Corporate Governance 
Navidea Biopharmaceuticals, Inc’s ISS Governance QuickScore as of Apr 1, 2014 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 6; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Mark Jerome Pykett V.M.D., Ph.D., MBA, 50
Chief Exec. Officer and Director
Dr. Thomas H. Tulip Ph.D., 61
Pres and Chief Bus. Officer
Mr. Brent L. Larson , 51
Chief Financial Officer, Principal Accounting Officer, Exec. VP, Sec. and Treasurer
Dr. Frederick O. Cope Ph.D., F.A.C.N., C.N.S., 67
Chief Scientific Officer and Sr. VP
Dr. Cornelia B. Reininger M.D., Ph.D., 61
Chief Medical Officer and Sr. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders